INTRODUCTION Microcatheter selection is an infrequent focus of stroke thrombectomy technique evaluation. The Headway27 microcatheter strikes an excellent balance of microcatheter dimensions (156 cm length, 2.6 Fr distal OD, ID 0.027 inches) and visibility, making it ideal for stroke thrombectomy. METHODS We evaluated a prospectively maintained acute stroke thrombectomy database containing 50 consecutive cases using the Headway27 microcatheter. From the database, patient demographics, clinical and angiographic information as well as procedural technical details and complications were extracted. RESULTS Manual aspiration thrombectomy (MAT) was performed alone in 72% of cases, stentriever-assisted MAT was performed in 6% of cases, and a combination was used in 22% of cases. Median groin puncture to final recanalization time was 27 min and mTICI 2B/3 recanalization was achieved in 94% of cases. There were 2 intra-procedural complications, neither related to the microcatheter. In all cases, the Headway27 reached the intended target vessel: M1 (n = 4), M2 (n = 26), M3 (n = 13), P2 (n = 3), P3 (n = 1), and basilar artery (n = 3). There were no cases requiring usage of an additional or alternative microcatheter. In 45/47 cases of MAT, the reperfusion catheter tracked over the Headway to the clot/intended target; in two cases, the microcatheter was used to deploy a stentriever that then allowed the reperfusion catheter to track to the clot. CONCLUSION The Headway27 microcatheter reliably facilitated rapid clot access in anterior and posterior circulation acute large vessel occlusions with no microcatheter-associated complications.

中文翻译：

---

眼见为实：Headway27 是一款高度可见且用途广泛的微导管，具有适合中风血栓切除术的理想尺寸。

引言 微导管选择是卒中取栓技术评估的一个罕见焦点。Headway27 微导管在微导管尺寸（156 厘米长，2.6 Fr 远端外径，ID 0.027 英寸）和可见度之间取得了极好的平衡，使其成为中风血栓切除术的理想选择。方法 我们使用 Headway27 微导管评估了一个前瞻性维护的急性卒中血栓切除术数据库，该数据库包含 50 个连续病例。从数据库中，提取了患者人口统计数据、临床和血管造影信息以及程序技术细节和并发症。结果 72% 的病例单独进行手动抽吸血栓切除术 (MAT)，6% 的病例使用支架辅助 MAT，22% 的病例联合使用。腹股沟穿刺到最终再通的中位时间为 27 分钟，94% 的病例实现了 mTICI 2B/3 再通。有 2 例术中并发症，均与微导管无关。在所有情况下，Headway27 均到达预期目标血管：M1 (n = 4)、M2 (n = 26)、M3 (n = 13)、P2 (n = 3)、P3 (n = 1) 和基底动脉（n = 3）。没有需要使用额外或替代微导管的病例。在 45/47 例 MAT 中，再灌注导管通过 Headway 跟踪到凝块/预期目标；在两个案例中，微导管被用来部署一个支架，然后让再灌注导管追踪到凝块。